What It Is
Livagen is a synthetic tetrapeptide built from four amino acids — lysine, glutamic acid, aspartic acid, and alanine — often abbreviated KEDA and listed in PubChem as H-Lys-Glu-Asp-Ala-OH.[1] It belongs to a category researchers call peptide bioregulators: short peptides studied mainly in Russian and Eastern European laboratories for possible effects on gene activity and cellular aging.
Livagen is not an approved medicine, a hormone, or a growth-factor drug. It is best understood as a laboratory research compound with a fairly narrow, specialized literature centered on chromatin biology, immune cells, and a handful of organ-culture studies.
How It Works
The central hypothesis behind Livagen involves chromatin — the tightly packed combination of DNA and protein inside a cell's nucleus that controls which genes are accessible for use. Researchers have proposed that Livagen can loosen, or "decondense," regions of chromatin that become more tightly packed with age, potentially reactivating genes — including ribosomal genes involved in protein production — that had become less active.[2][3]
This idea is biologically plausible and has generated real laboratory findings, but a peptide loosening chromatin structure in a cultured cell is a long way from a proven anti-aging or disease-modifying effect in a living person. Mechanism explains why a compound is worth studying; it does not by itself demonstrate clinical benefit.
What the Research Shows
Livagen's evidence base is built almost entirely from laboratory and ex vivo work rather than patient trials. Key studies include chromatin decondensation and ribosomal gene activation in lymphocytes taken from older adults, ranging from age 75 to 88 in one study.[2][3] A separate human-serum assay found that Livagen inhibited enkephalin-degrading enzymes with an IC50 of about 20 micromolar, while showing no measurable binding to opioid receptors in rat brain tissue.[7]
Additional findings come from rat hepatocyte cultures examining protein-synthesis rhythms and a rat study of oral Livagen affecting digestive-enzyme activity differently in young versus old animals.[8][10] These are informative laboratory and animal results, not evidence of benefit in humans. No randomized controlled human trial measuring patient-level outcomes — symptoms, organ function, survival, or quality of life — appears in the literature reviewed for Livagen.
Safety & Side Effects
Because Livagen has never gone through the clinical development process required for drug approval, there is no adverse-event database, no labeled warning list, and no post-marketing surveillance data of the kind that exists for approved medications. This is a genuine gap, not a sign of a clean safety record.
General commentary on injectable research peptides — not necessarily Livagen specifically — points to potential concerns such as injection-site irritation, fatigue, headache, and gastrointestinal symptoms, but these figures cannot be assumed to apply to Livagen at any particular rate.[22] Long-term safety, immunogenicity, drug interactions, and use during pregnancy or breastfeeding remain entirely uncharacterized for this compound.
Regulatory Status
Livagen does not have an FDA-approved prescribing label. It does not appear in Drugs@FDA or the FDA's Orange Book of approved drug products, and no current listing for it was found in DailyMed, the U.S. repository of official drug labeling.[17][18][19]
FDA guidance on unapproved drugs notes that such products can carry risks tied to unreviewed formulations, unverified manufacturing processes, and a lack of documented evidence of effectiveness.[20] Livagen should be treated strictly as an investigational research compound; any product sold under this name has not been evaluated by regulators for safety, purity, or efficacy in humans.
Related Bioregulator Peptides
Livagen is frequently discussed alongside other short peptide bioregulators from the same research tradition, particularly Epitalon (also spelled Epithalon) and Vilon, which appear in overlapping chromatin and aging studies.[6][7] In the enkephalin-degrading enzyme study, Livagen and Epitalon were tested side by side, with Livagen showing greater enzyme-inhibiting potency in that specific assay — a biochemical comparison, not a ranking of clinical effectiveness or safety.
These peptides share a research lineage but each has a distinct sequence, mechanism, and evidence base. None of them should be treated as interchangeable, and none currently carries FDA approval or an established human safety profile.